cGVHDChronic Graft Versus Host Disease
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The serial measurement of tear volume in mice with cGVHD revealed that the tear production was gradually declined.
(3) Eczematoid GVHD is a form of chronic cutaneous GVHD (cGVHD) which has been recently reported by Creamer et al.
Recent dates have shown that Th17 pathway is associated with cGVHD [6].
Although G-PBSC are enriched in progenitor cells as compared to SS-BM, which allows a faster engraftment, [sup][1] the use of G-PBSC will increase the incidence of chronic graft-versus-host disease (cGVHD).
M2 PHARMA-July 26, 2017-Kadmon Provides Supplemental Data from Trial of Kinase Inhibitor in cGVHD
Based on the FDA's guidance, Kadmon plans to initiate an open-label, two-arm, pivotal Phase 2 clinical trial to support the potential registration of KD025 in cGVHD. In the planned pivotal trial, patients will be randomized to receive one of two dose levels of KD025: 200 mg QD or 200 mg BID; 48 patients will be enrolled into each arm.
In October 2017, KD025 received orphan drug designation from the FDA for cGVHD.
(NYSE: KDMN) today announced that KD025-213, an open-label registration trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD), is fully enrolled.
FDA regarding KD025 in cGVHD. KD025-213 is an open-label registration trial of KD025 in adults and adolescents with cGVHD who have received at least two prior lines of systemic therapy.
Previously, GvHD has been defined on the basis of the time of occurrence: aGvHD in the first 100 days vs chronic GvHD (cGvHD) 100 days after transplantation (6).
GRAVITAS-309 (NCT03584516) is a randomized, double-blind, placebo-controlled pivotal Phase 3 study evaluating itacitinib or placebo in combination with corticosteroids as a first-line treatment for patients with chronic graft-versus-host disease (cGVHD).